Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Bokemeyer

Showing results (21-30 of 663) with videos related to

Pageof 67
Sort By:
BJU International|October 21, 2009
High-dose chemotherapy in nonseminomatous germ cell cancerChristian Kollmannsberger, Joerg Beyer, Carsten Bokemeyer
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Current standards and new trends in the primary treatment of colorectal cancerAlexander Stein, Djordje Atanackovic, Carsten Bokemeyer
Journal of Oncology|May 22, 2010
Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?Jasmin Otten, Carsten Bokemeyer, Walter Fiedler
The New England Journal of Medicine|October 31, 2007
Germ-cell tumorsAnja Lorch, Jörg Beyer, Carsten Bokemeyer
Seminars in Hematology|July 17, 2007
Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelinesMichael Heuser, Arnold Ganser, Carsten Bokemeyer, et al.
Deutsches Arzteblatt International|June 28, 2023
Testicular TumorsSusanne Krege, Christoph Oing, Carsten Bokemeyer
Expert Review of Anticancer Therapy|March 9, 2018
Therapeutic approaches for refractory germ cell cancerChristoph Oing, Christoph Seidel, Carsten Bokemeyer
Cancer Treatment Reviews|March 30, 2010
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapyDiane Seimetz, Horst Lindhofer, Carsten Bokemeyer
Cancer Management and Research|December 29, 2010
Evolving role of cetuximab in the treatment of colorectal cancerGunter Schuch, Sebastian Kobold, Carsten Bokemeyer
Journal of Cancer Research and Clinical Oncology|September 18, 2009
Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumorsKarin Oechsle, Carsten Bokemeyer, Friedemann Honecker
Pageof 67

Showing results (21-30 of 663) with videos related to

Sort By:
Pageof 67
BJU International|October 21, 2009
High-dose chemotherapy in nonseminomatous germ cell cancerChristian Kollmannsberger, Joerg Beyer, Carsten Bokemeyer
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Current standards and new trends in the primary treatment of colorectal cancerAlexander Stein, Djordje Atanackovic, Carsten Bokemeyer
Journal of Oncology|May 22, 2010
Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?Jasmin Otten, Carsten Bokemeyer, Walter Fiedler
The New England Journal of Medicine|October 31, 2007
Germ-cell tumorsAnja Lorch, Jörg Beyer, Carsten Bokemeyer
Seminars in Hematology|July 17, 2007
Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelinesMichael Heuser, Arnold Ganser, Carsten Bokemeyer, et al.
Deutsches Arzteblatt International|June 28, 2023
Testicular TumorsSusanne Krege, Christoph Oing, Carsten Bokemeyer
Expert Review of Anticancer Therapy|March 9, 2018
Therapeutic approaches for refractory germ cell cancerChristoph Oing, Christoph Seidel, Carsten Bokemeyer
Cancer Treatment Reviews|March 30, 2010
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapyDiane Seimetz, Horst Lindhofer, Carsten Bokemeyer
Cancer Management and Research|December 29, 2010
Evolving role of cetuximab in the treatment of colorectal cancerGunter Schuch, Sebastian Kobold, Carsten Bokemeyer
Journal of Cancer Research and Clinical Oncology|September 18, 2009
Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumorsKarin Oechsle, Carsten Bokemeyer, Friedemann Honecker
Pageof 67